Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-05-10
2011-05-10
Brusca, John S (Department: 1631)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C702S020000
Reexamination Certificate
active
07939261
ABSTRACT:
The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
REFERENCES:
patent: 4699877 (1987-10-01), Cline et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5015568 (1991-05-01), Tsujimoto et al.
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5459251 (1995-10-01), Tsujimoto et al.
patent: RE35491 (1997-04-01), Cline et al.
patent: 5670325 (1997-09-01), Lapidus et al.
patent: 5741650 (1998-04-01), Lapidus et al.
patent: 5830665 (1998-11-01), Shuber et al.
patent: 5830753 (1998-11-01), Coulie et al.
patent: 5858678 (1999-01-01), Chinnadurai
patent: 5861278 (1999-01-01), Wong et al.
patent: 5928870 (1999-07-01), Lapidus et al.
patent: 5952178 (1999-09-01), Lapidus et al.
patent: 5952179 (1999-09-01), Chinnadurai
patent: 5962312 (1999-10-01), Plowman et al.
patent: 5985553 (1999-11-01), King et al.
patent: 6020137 (2000-02-01), Lapidus et al.
patent: 6100029 (2000-08-01), Lapidus et al.
patent: 6143529 (2000-11-01), Lapidus et al.
patent: 6146828 (2000-11-01), Lapidus et al.
patent: 6171798 (2001-01-01), Levine et al.
patent: 6203993 (2001-03-01), Shuber et al.
patent: 6207401 (2001-03-01), Plowman et al.
patent: 6207452 (2001-03-01), Govindaswamy
patent: 6214558 (2001-04-01), Shuber et al.
patent: 6245523 (2001-06-01), Altieri
patent: 6248535 (2001-06-01), Danenberg et al.
patent: 6271002 (2001-08-01), Linsley et al.
patent: 6322986 (2001-11-01), Ross
patent: 6414134 (2002-07-01), Reed
patent: 6582919 (2003-06-01), Danenberg
patent: 6602670 (2003-08-01), Danenberg
patent: 6618679 (2003-09-01), Loehrlein et al.
patent: 6620606 (2003-09-01), Bandman et al.
patent: 6696558 (2004-02-01), Reed et al.
patent: 6716575 (2004-04-01), Plowman et al.
patent: 6750013 (2004-06-01), Gish et al.
patent: 6800737 (2004-10-01), Altieri
patent: 6943150 (2005-09-01), Altieri
patent: 2002/0004491 (2002-01-01), Xu et al.
patent: 2002/0009736 (2002-01-01), Wang
patent: 2002/0039764 (2002-04-01), Rosen et al.
patent: 2002/0160395 (2002-10-01), Altieri et al.
patent: 2003/0073112 (2003-04-01), Zhang et al.
patent: 2003/0104499 (2003-06-01), Pressman et al.
patent: 2003/0165952 (2003-09-01), Linnarsson et al.
patent: 2003/0180791 (2003-09-01), Chinnadurai
patent: 2003/0198970 (2003-10-01), Roberts
patent: 2003/0198972 (2003-10-01), Erlander et al.
patent: 2003/0219771 (2003-11-01), Bevilacqua et al.
patent: 2003/0229455 (2003-12-01), Bevilacqua et al.
patent: 2004/0009489 (2004-01-01), Golub et al.
patent: 2004/0126775 (2004-07-01), Altieri et al.
patent: 2004/0133352 (2004-07-01), Bevilacqua et al.
patent: 2004/0209290 (2004-10-01), Cobleigh et al.
patent: 0108564 (1988-05-01), None
patent: 1365034 (2003-11-01), None
patent: 99/02714 (1999-01-01), None
patent: 00/50595 (2000-08-01), None
patent: 00/55173 (2000-09-01), None
patent: 01/70979 (2001-03-01), None
patent: 01/25250 (2001-04-01), None
patent: 01/40466 (2001-06-01), None
patent: 01/55320 (2001-08-01), None
patent: 02/00677 (2002-01-01), None
patent: 02/06526 (2002-01-01), None
patent: 02/08260 (2002-01-01), None
patent: 02/08261 (2002-01-01), None
patent: 02/08282 (2002-01-01), None
patent: 02/08765 (2002-01-01), None
patent: 02/17852 (2002-03-01), None
patent: 02/46467 (2002-06-01), None
patent: 02/55988 (2002-07-01), None
patent: 02/059377 (2002-08-01), None
patent: 02/068579 (2002-09-01), None
patent: 02/103320 (2002-12-01), None
patent: 03/011897 (2003-02-01), None
patent: 03/083096 (2003-10-01), None
Abrahamsen, et al., Towards Quantitative mRNA Analysis in Paraffin-Embedded Tissues Using Real-Time Reverse Transcriptase-Polymerase Chain Reaction, J Mol Diagn. Feb. 2003; 5(1):34-41.
Castiglione, et al., Bcl2, p. 53 and clinical outcome in a series of 138 operable breast cancer patients, Anticancer Res. Sep.-Oct. 1999;19(5C):4555-63.
Nogi, et al., Detection of MUC1 and keratin 19 mRNAs in the bone marrow by quantitative RT-PCR predicts the risk of distant metastasis in breast cancer patients, Breast Cancer. 2003;10(1):74-81.
Van'tveer, et al., Gene expression profiling predicts clincial outcome of breast cancer, Nature. Jan. 31, 2002; 415 (6871):530-6.
Abba et al., Gene expression signature of estrogen receptor a status in breast cancer. BMC Genomics 2005; 6:37.
Bertucci et al., Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Human Molecular Genetics 2000;9(20):2981-91.
Callagy et al., BCL-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin. Cancer Res. 2006; 12 (8):2468-75.
Chenard, et al.,High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma.
Engel, et al., Correlation between stromelysin-3 mRNA level and outcome of human breast cancer, International Journal of Cancer, vol. 58 Issue 6, Jul. 17, 2006, pp. 830-835.
Fisher et al., Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from national surgical adjuvant breast and bowel project protocol B-06.
Gasparini et al., Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clinical Cancer Research 1995; 1(189-190):189-98.
Glinsky et al., Microarray analysis identifies a death-from=cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Investigation 2005; 115(6):1503-21.
Kononen et al., Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine 1998; 4(7):844-7.
Lah et al., Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: Comparison with cathespin D, cathespin L, and other clinical indicators. Clinical Cancer Research 2000;6:578-84.
Miyoshi et al., Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer 2001; 92:370-3.
Span et al., Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clinical Chemistry 2004; 50 (11):1986-93.
Stefano et al. Expression levels and clinical-pathological correlations of HER2
eu in primary and metastatic human breast cancer. Ann. N. Y. Acad. Sci. 2004; 1028:463-72.
Stein, et al., The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer.
Tanaka et al., Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Research 1999; 59:2041-4.
Tanaka et al., Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clinical Cancer Research 2000; 6:127-34.
Townsend, et al., BAG-1 expression in human breast cancer: interrelationship between BAG-1 RNA, protein, HSC70 expression and clinico-pathological data, Journal of Pathology, 197, (1), 51-59.
Turner et al., BAG-1: A novel biomarker predicting long-term survival in early stage breast cancer. J. Clin. Oncol. 2001;19(4):992-1000.
Urruticoechea et al., Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncology 23:7212-20.
Valkovic, et al., Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma, Virchows Archiv, vol. 440, No. 6 / Jun. 2002, 583-588.
Van De Vijver et al., A gene-expression signature as a predictor of survival in breast cancer. New Eng. J. Med. 2002; 347(25):1999-2009.
Van'T Veer et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.
Bhattacharjee et al., Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. PNAS 2001;98(24):13790-5.
Brabender et al., Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Canc Re
Baker Joffre B.
Bryant John L.
Paik Soonmyung
Shak Steven
Borden Paula A.
Bozicevic Field and Francis LLP
Brusca John S
Genomic Health, Inc.
NSABP Foundation, Inc.
LandOfFree
Expression profile algorithm and test for cancer prognosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression profile algorithm and test for cancer prognosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression profile algorithm and test for cancer prognosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2647796